Companies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality Lotus notes that NRx has “achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression. The readout for…